Home/Filings/4/0001209191-08-067579
4//SEC Filing

MUNDKUR CHRISTINE 4

Accession 0001209191-08-067579

CIK 0000010081other

Filed

Dec 28, 7:00 PM ET

Accepted

Dec 29, 5:43 PM ET

Size

25.5 KB

Accession

0001209191-08-067579

Insider Transaction Report

Form 4
Period: 2008-12-23
MUNDKUR CHRISTINE
Sr.VP, Quality and Reg Counsel
Transactions
  • Disposition to Issuer

    Stock Appreciation Rights

    2008-12-2327,8720 total
    Exercise: $46.99Exp: 2015-07-27Common Stock (27,872 underlying)
  • Disposition to Issuer

    Stock Appreciation Rights

    2008-12-2330,0000 total
    Exercise: $48.80From: 2008-11-11Exp: 2016-07-26Common Stock (30,000 underlying)
  • Disposition to Issuer

    Common Stock

    2008-12-235,4060 total
  • Disposition to Issuer

    Stock Options

    2008-12-2342,6900 total
    Exercise: $43.34Exp: 2013-07-30Common Stock (42,690 underlying)
  • Disposition to Issuer

    Stock Options

    2008-12-2327,1440 total
    Exercise: $35.01Exp: 2014-08-04Common Stock (27,144 underlying)
  • Disposition to Issuer

    Stock Options

    2008-12-2342,7210 total
    Exercise: $26.58Exp: 2012-08-07Common Stock (42,721 underlying)
  • Disposition to Issuer

    Stock Appreciation Rights

    2008-12-2315,0000 total
    Exercise: $49.49From: 2008-11-11Exp: 2017-03-07Common Stock (15,000 underlying)
  • Disposition to Issuer

    Stock Appreciation Rights

    2008-12-2375,0000 total
    Exercise: $49.22From: 2008-11-11Exp: 2018-03-04Common Stock (75,000 underlying)
Footnotes (10)
  • [F1]Disposed of pursuant to a merger agreement between Issuer and Teva Pharmaceutical Industries Ltd. in exchange for 3391 shares of Teva Common Stock having a market value of $41.82 per share on the effective date of the merger and cash in the amount of $215,738.25.
  • [F10]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $1,296,000, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.22 per share.
  • [F2]Option vested equally over a 3 year period from grant date
  • [F3]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $1,705,422.32, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $26.58 per share.
  • [F4]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $988,700.40, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $43.34 per share.
  • [F5]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $854,764.56, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $35.01 per share.
  • [F6]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $543,782.72, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $46.99 per share.
  • [F7]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $531,000, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $48.80 per share.
  • [F8]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $255,155, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.49 per share.
  • [F9]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $320,700, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $55.81 per share.

Issuer

BARR PHARMACEUTICALS INC

CIK 0000010081

Entity typeother

Related Parties

1
  • filerCIK 0001237264

Filing Metadata

Form type
4
Filed
Dec 28, 7:00 PM ET
Accepted
Dec 29, 5:43 PM ET
Size
25.5 KB